Effects of fibrinogen receptor antagonist GR144053F and aurintricarboxylic acid on platelet activation and degranulation 1 1 Abbreviations: ACD, citric acid/trisodium citrate/glucose (recipe A), blood anticoagulant; ATA, aurintricarboxylic acid; CTCADP, closure (occlusion) time determined with the use of collagen/ADP cassettes in PFA-100; GPIb-IX-V, a complex of glycoproteins Ib, IX, and V, a vWF receptor; GPIIb-IIIa, a complex of glycoproteins IIb and IIIa, a fibrinogen receptor; ic 50, the concentration of an inhibitor, at which 50% of the maximal estimated inhibition occurred; the extent of maximal inhibition was calculated based on the mathematical resolving of the equation describing the inhibition of platelet aggregation; PE, R-phycoerythrin; PFA-100™, platelet function analyzer; PRP, platelet-rich plasma; RGD, Arg-Gly-Asp; PBS, phosphate-buffered saline; TRAP, thrombin receptor activating peptide, SFLLRNPNDKYEPF; and vWF, von Willebrand factor.
Titel:
Effects of fibrinogen receptor antagonist GR144053F and aurintricarboxylic acid on platelet activation and degranulation 1 1 Abbreviations: ACD, citric acid/trisodium citrate/glucose (recipe A), blood anticoagulant; ATA, aurintricarboxylic acid; CTCADP, closure (occlusion) time determined with the use of collagen/ADP cassettes in PFA-100; GPIb-IX-V, a complex of glycoproteins Ib, IX, and V, a vWF receptor; GPIIb-IIIa, a complex of glycoproteins IIb and IIIa, a fibrinogen receptor; ic 50, the concentration of an inhibitor, at which 50% of the maximal estimated inhibition occurred; the extent of maximal inhibition was calculated based on the mathematical resolving of the equation describing the inhibition of platelet aggregation; PE, R-phycoerythrin; PFA-100™, platelet function analyzer; PRP, platelet-rich plasma; RGD, Arg-Gly-Asp; PBS, phosphate-buffered saline; TRAP, thrombin receptor activating peptide, SFLLRNPNDKYEPF; and vWF, von Willebrand factor.
Auteur:
Rozalski, Marcin Boncler, Magdalena Golanski, Jacek Watala, Cezary